tirzepatide latham tirzepatide latham Compound Tirzepatide

4 SURMOUNT-3 study design

Advertisement Supported by Users of New Weight Loss Drug Had Lower Blood Pressure in Study The patients used tirzepatide, sold as Mounjaro or Zepbound, but researchers could not distinguish the effect of the drug from the effects of weight loss

Clinical studies show tirzepatide reduces HbA1c by 2-3%, substantially more than GLP-1 monotherapy

Maternal multiple micronutrient supplementation in rural Pakistan increased some milk micronutrient concentrations, but not infant growth, at three-months postpartum: a randomized controlled trial substudy

This precaution is particularly important given the potential for reduced oral contraceptive absorption due to delayed gastric emptying, not due to weight loss itself

The reduced caloric intake combined with altered gastric motility creates a perfect storm for nutritional insufficiency, particularly in patients who remain on treatment for more than six months